Loading...
•
Sep 30, 2022
Jaguar Health Q3 2022 Earnings Report
Reported consolidated third-quarter 2022 financial results and provided company updates.
Key Takeaways
Jaguar Health reported a combined net revenue of approximately $3.1 million for Mytesi® and Canalevia®-CA1 in Q3 2022, representing an increase of 8.2% over Q2 2022 and 412% over Q3 2021.
Prescription product net revenue increased 8.2% over Q2 2022 and 412% over Q3 2021.
Mytesi total prescription volume increased approximately 3% in Q3 2022 over Q2 2022.
OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) adding international sites, targeting completion of enrollment in Q2 2023.
Second conditional approval for Canalevia®, for exercise-induced diarrhea (EID), expected in Q1 2023.
Forward Guidance
Jaguar Health anticipates several key milestones, including the completion of enrollment in the OnTarget Phase 3 clinical trial in Q2 2023, potential conditional approval for Canalevia for EID in Q1 2023, and business development activities with nondilutive funding for Jaguar’s mental health Entheogen Therapeutics Initiative (ETI) program targeted for Q1 2023.
Positive Outlook
- Completion of enrollment in the OnTarget Phase 3 clinical trial in Q2 2023.
- Potential conditional approval for Canalevia for EID in Q1 2023.
- Business development activities with nondilutive funding for Jaguar’s mental health Entheogen Therapeutics Initiative (ETI) program targeted for Q1 2023.
- Expected presentation in December 2022 from a third-party investigator following initiation of proof-of-concept trial of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CCD).
- Additional investigator-initiated requests and trials and clinical data for SBS and CDD are expected to come throughout 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...